MGMT and glioblastoma: Notably, low and medium RYK expression levels were identified as significant risk factors for OS in GBM, IDH wildtype patients who were MGMT methylated (HR = 0.37; 95% CI, 0.15–0.92, p = 0.033 and HR = 0.36; 95% CI, 0.14–0.92, p = 0.032, respectively) (Supplementary Figure S9f).